Tag: enough

  • COVID-19: Media Group Calls For Increased Welfare For Journalists

    COVID-19: Media Group Calls For Increased Welfare For Journalists

    Journalists
    Journalists

    Media/civil society groups have demanded increased welfare of journalists during the outbreak of COVID-19.

    The groups also called for special protection and support for journalists covering the outbreak of the virus in Nigeria.

    The groups made the demand following a survey to assess the support available to journalists for their safety in covering the COVID-19 pandemic. 

    COVID-19: Media Group Calls For Increased Welfare For Journalists 1Journalists


    The Wole Soyinka Centre for Investigative Journalism, Enough is Enough, International Press Centre, the International Centre for Investigative Reporting, and Premium Times Centre for Investigative Journalism, commissioned the survey following perceptions that journalists were being exposed to danger in the course of covering the pandemic.

    The survey, filed by 463 journalists — correspondents, reporters, editors, freelancers and presenters from 73 print, broadcast and online media across 33 states and the Federal Capital Territory – revealed that there has been a poor attention to the needs, safety and welfare of journalists covering the pandemic.

    Drawing from responses from the survey, the media/civil society groups have urged media proprietors to ensure that reporters on the field are adequately insured and financially empowered as they urged media outfits owing salaries to immediately pay their journalists.

    They also demanded that media organisations should, “Establish workplace policy and follow the same to equip their journalists with specialised and personal protective equipment including for observation of social distancing while on the field.

    “Provide training to journalists on how to crowd source information for their stories without having to necessarily go to the field; and explore technological options for interviews while in-house infrastructure should be put in place to ensure the safety of employees and guests (particularly for broadcast media) in line with the safety advisory of the government and health authorities.”

    They also enjoined freelance journalists to take advantage of reporting grants and other opportunities to procure personal protective equipment while covering the pandemic.

    Following the outbreak, media outfits are beginning to introduce reduction in salaries, with organisations citing economic importance as reason for the deduction.

     

    Journalism

    MEDIA

    News

    AddThis

    : 

    Original Author

    : 

    SaharaReporters, New York

    Disable advertisements

    : 
    COVID-19: Media Group Calls For Increased Welfare For Journalists
    Read More
    http://saharareporters.com/2020/05/08/covid-19-media-group-calls-increased-welfare-journalists

    Views: 0

  • New estimates highlight need to step up the response to hepatitis D

    Lyon, France, 29 April 2020 – In a study published in the Journal of Hepatology, 1 Professor Anna Maria Geretti and Dr Alexander Stockdale from the University of Liverpool (United Kingdom), in collaboration with researchers
    from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), estimate that worldwide, hepatitis D virus (HDV) affects nearly 5% of people who have a chronic infection with hepatitis B virus (HBV) and that HDV
    co-infection could explain about 1 in 5 cases of liver disease and liver cancer in people with HBV infection..

    To map the epidemiology of HDV infection in the world, Professor Geretti and Dr Stockdale joined forces with the WHO Global Hepatitis Programme and IARC, alongside investigators in Germany, Malawi, and the United Kingdom. “Infection with HDV occurs
    in about 1 in 22 cases of chronic HBV infection in the world,” Dr Stockdale says. “More high-quality data are needed, but we have identified several geographical hotspots of high prevalence of HDV infection: in Mongolia, the Republic of
    Moldova, and countries in Western and Middle Africa.”

    “Although it is less common than hepatitis B, hepatitis D is a serious disease that often affects underprivileged and vulnerable populations,” says Dr Meg Doherty, Director of the WHO Global Hepatitis Programme. Those who are more likely to
    have HBV and HDV co-infection include people who inject drugs and people with hepatitis C virus or HIV infection. The risk of co-infection also appears to be higher in recipients of haemodialysis, men who have sex with men, and commercial sex workers.
    Dr Doherty points out, “This information helps in identifying the groups with HBV among whom we should be looking for HDV.”

    HDV (formerly known as the Delta agent) is a small virus – one of the smallest that is known to cause disease in humans – and can replicate only in the presence of HBV, from which HDV borrows some of its structures. Compared with people with
    HBV infection alone, those who have a chronic infection with both HBV and HDV have a much higher risk of developing disease in the form of cirrhosis and liver cancer. “HDV is a significant contributor to severe liver disease and liver cancer,”
    says IARC scientist Dr Catherine de Martel. “The findings from this study inform our work on the association between viral infections and cancer, which is focused on developing improved prevention strategies.”

    Professor Geretti concludes, “HDV has long been neglected, because for decades the prevalence of infection remained uncertain and effective treatment was lacking. Mapping the epidemiology of the infection is just the first step. More efforts are
    needed to reduce the global burden of chronic hepatitis B and develop medicines that are safe and effective against hepatitis D and are affordable enough to be deployed on a large scale to those who are most in need.”

    1 Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM (2020). The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. Published online 23 April 2020;
    https://doi.org/10.1016/j.jhep.2020.04.008

    For more information, please contact

    Véronique Terrasse, Communications Group, at +33 (0)6 45 28 49 52 or terrassev@iarc.fr or IARC Communications, at com@iarc.fr

    The International Agency for Research on Cancer (IARC) is part of the World Health Organization. Its mission is to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for
    cancer control. The Agency is involved in both epidemiological and laboratory research and disseminates scientific information through publications, meetings, courses, and fellowships. If you wish your name to be removed from our press release emailing
    list, please write to com@iarc.fr. 

    About University of Liverpool

    Founded in 1881 as the original ‘red brick’, the University of Liverpool is one of the UK’s leading research-intensive higher education institutions. Consistently ranked in the top 200 universities worldwide, we are a member of the prestigious
    Russell Group and have a global reach and influence that reflects our academic heritage as one of the country’s largest civic institutions. For more information please visit us at www.liverpool.ac.uk

    Read More
    https://www.who.int/news-room/detail/29-04-2020-new-estimates-highlight-need-to-step-up-the-response-to-hepatitis-d

    Views: 0

  • New FAQs address healthcare workers questions on breastfeeding and COVID-19

    New FAQs address healthcare workers questions on breastfeeding and COVID-19

    Mothers and healthcare workers who support them have many questions and concerns about whether it is safe for mothers with confirmed or suspected COVID-19 to be close to and breastfeed their babies during the pandemic.

    To address their questions, WHO has released a list of Frequently asked questions: Breastfeeding and COVID-19. The FAQ complements the WHO interim guidance: Clinical management of severe acute respiratory infection when COVID-19 is suspected and draws upon other WHO recommendations on infant and young child feeding.

    The FAQs aim to provide information to healthcare workers supporting mothers and families in maternity services and community settings, and communicate how the interim guidance should be implemented. Additionally, the FAQs provide information about the protective effects of breastfeeding and skin-to-skin contact, and the harmful effects of inappropriate use of infant formula milk.

    Accompanying the FAQs is a decision tree which provides step-by-step guidance to health workers on how to support mothers with confirmed or suspected COVID-19 to breastfeed. It provides advice on what to do if mothers are not well enough to breastfeed, as well as appropriate hygiene measures for mothers, including wearing a medical mask if available, to reduce the possibility of the COVID-19 virus being spread to her infant.

    Benefits of breastfeeding outweigh potential risks

    The COVID-19 virus has not been detected in the breastmilk of any mother with confirmed and suspected COVID-19 and there is no evidence so far that the virus is transmitted through breastfeeding. Researchers continue to test breastmilk from mothers with the infection.

    WHO recommends that all mothers with confirmed or suspected COVID-19 continue to have skin-to-skin contact and to breastfeed. In all socio-economic settings, breastfeeding improves survival and provides lifelong health and development advantages to newborns and infants. Breastfeeding also reduces the risk of breast and ovarian cancer for the mother. Skin-to-skin contact, including kangaroo mother care, reduces neonatal mortality, especially for low birth weight newborns.

    While infants and children can contract COVID-19, they are at low risk of infection. The few confirmed cases of COVID-19 in young children to date have experienced only mild or asymptomatic illness.

    WHO’s recommendations on the care and feeding of infants whose mothers have confirmed or suspected COVID-19 aim to improve the immediate and lifelong survival, health and development of their newborns and infants. These recommendations consider the likelihood and potential risks of COVID-19 in infants and also the risks of serious illness and death when infants are not breastfed or when infant formula milk are used inappropriately.

    WHO’s Q&A on breastfeeding and COVID-19 also provides additional infection prevention advice to mothers with confirmed or suspected COVID-19.

    New FAQs address healthcare workers questions on breastfeeding and COVID-19
    Read More
    https://www.who.int/news-room/detail/28-04-2020-new-faqs-address-healthcare-workers-questions-on-breastfeeding-and-covid-19

    Views: 0

  • Maternal infections in health facilities

    Maternal infections in health facilities

    A clearer picture of the global impact 

    New research from the Global Maternal Sepsis Study (GLOSS), a major WHO/HRP initiative, shows that infection has a much larger impact on global maternal mortality and morbidity than previously thought.

    Logo of the Lancet Global HealthThe
    results from GLOSS, published in The Lancet Global Health, are the first to provide data on frequency of maternal infections and
    sepsis across the pregnancy and post-pregnancy period, in a large number of health facilities around the world. 

    Around 11 women per 1000 live births had an infection which resulted in or contributed to what is known as a severe maternal outcome – either they died or nearly died – during their hospitalization. 

    Urgent improvement is needed to manage this life-threatening risk faced by all pregnant and recently pregnant women, wherever they are in the world. 

    What is maternal sepsis and how does it lead to maternal death?

    Maternal sepsis is a life-threatening condition that arises when the body’s response to infection causes injury to its own tissues and organs during pregnancy, child-birth, post-abortion or the postpartum period.

    The latest global estimates place sepsis due to obstetric infections as the third most common cause of maternal mortality. However, this only includes infections as a direct result of pregnancy, such as endometritis or post-caesarean wound infections.

    Few
    previous studies include post-abortion infections. Neither do they address indirect infections such as respiratory and meningitis, which are aggravated by pregnancy but not directly caused by it.

    A better understanding of maternal infection

    GLOSS was a massive facility-based data collection effort led by WHO, accompanied by a ‘STOP SEPSIS!’ campaign to increase awareness among healthcare providers.

    The study gathered data on women who were admitted with suspected or confirmed infection during pregnancy or post-pregnancy over a one-week period in 2017. More than 2800 women participated in the study in 52 countries.

    GLOSS included healthcare facilities that care for women during pregnancy, childbirth or at the end of pregnancy, as well as facilities without maternity service but where women could be hospitalized during or after pregnancy, and data on infections
    which are not usually recorded as maternal sepsis, including post-abortion and indirect infections. 

    The result is a more complete understanding of the frequency and impact of maternal infections in health facilities. 

    GLOSS calls attention not only to the wider range of risks faced by pregnant women but also to the long period of time during which they are at risk. 

    Putting global numbers on maternal infection and sepsis

    Overall, around 70 pregnant or recently-pregnant women per 1000 live births were found to have a maternal infection needing hospital management. 

    Across the study, 11 women with either direct or indirect infection per 1000 live births developed a severe maternal outcome, but in low- and middle-income countries up to 15 women per 1000 births were affected.

    Infections were the underlying cause of most of the deaths recorded during the study, primarily post-abortion infection and indirect infections. Infections were also present in about a third of deaths attributed to other causes, such as postpartum
    haemorrhage.

    This suggests that the contribution of infection to global maternal mortality and morbidity may be larger than current reports of maternal sepsis mortality suggest.

    Preventing, identifying and treating maternal infection and sepsis

    Some of the most common maternal infections found in the study, such as urinary tract infections, post-caesarean and post-abortion infections, are largely preventable and treatable.

    GLOSS results suggest that current levels of monitoring and clinical care across health facilities are not enough to prevent, identify and treat levels of maternal infection effectively. 

    For instance, a complete set of vital signs was not reported for a third of the women in the study, on the day their infection was suspected or diagnosed. Delays in antimicrobial therapy were frequent.

    GLOSS also shows marked differences across countries, with the highest burden in low- and middle-income countries, compared with high-income countries.

    This may reflect the impact of broader health determinants in different country contexts. Challenges of overcrowding, limited access to water and sanitation and constraints to safe births by skilled birth attendants can reduce the ability of healthcare
    providers to manage the frequency and outcome of maternal infections.

    An opportunity to implement evidence-based practice

    GLOSS gives healthcare providers, policy-makers, and the public at large an opportunity: to mobilise around these data improve evidence-based practice, and save lives. 

    WHO has produced a number of resources which can support timely action to prevent, diagnose and treat maternal infection, as well as activities such as the upcoming SAVE LIVES: Clean Your Hands campaign
    on 5 May which celebrates the central role played by nurses and midwives in clean health care. 

    In addition, WHO will publish a global sepsis epidemiology report around the 73rd World Health Assembly (WHA) in May, as requested in the
    2017
    WHA Resolution on Improving the prevention, diagnosis and clinical managementof sepsis.

    Understanding why and how infection affects women is essential for equipping healthcare providers with life-saving knowledge and enabling health care systems to bring down global maternal mortality and morbidity.

    Related publications

    WHO recommendations for prevention and treatment of maternal peripartum infections

    WHO Clinical practice handbook for safe abortion

    Global guidelines on the prevention of surgical site infection

    WHO statement on maternal sepsis

    World Health Assembly resolution on Improving the prevention, diagnosis and clinical management of sepsis

    Health Topics

    Antimicrobial resistance

    Infection Prevention and Control

    Water Sanitation Hygiene

    Other links

    Global Maternal Sepsis Study

    SAVE LIVES: Clean Your Hands 5 May 2020

     

     

    Maternal infections in health facilities
    Read More
    https://www.who.int/news-room/detail/27-04-2020-maternal-infections-in-health-facilities

    Views: 0

  • Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies

    Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies

    Our Vision and Mission

    Grounded in a vision of a planet protected from human suffering
    and the devastating social and economic consequences of
    COVID-19, we, an initial group of global health actors (BMGF,
    CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust, WHO) and
    private sector partners and other stakeholders, are launching
    a landmark, global and time-limited collaboration to accelerate the
    development, production and equitable global access to new COVID-19 essential health technologies.

    We know that as long as anyone is at risk from this virus, the entire
    world is at risk – every single person on the planet needs to be
    protected from this disease.

    We agree that alongside evidence-based public health measures,
    innovative COVID-19 diagnostics, therapeutics and vaccines are
    needed – in record time and at record scale and access – to save
    millions of lives and countless trillions of dollars, and to return
    the world to a sense of ‘normalcy’.

    We recognize the significant amount of critical work, investment
    and initiatives already ongoing around the world to expedite
    the development and deployment of innovative COVID-19 related
    products and interventions.

    We appreciate that while development and deployment of
    innovative products is essential, it will not be enough. We must
    simultaneously and urgently accelerate the strengthening of
    sustainable health systems and capacities to enable delivery of
    the new COVID-19 tools to those who need them and to mitigate
    the knock-on impact on other diseases.

    We remember lessons from the past, which have shown that even
    when effective tools are available to the world, too often some
    are protected, while others are not. This inequity is unacceptable –
    all tools to address COVID-19 must be available to all. In the fight
    against COVID-19, no one should be left behind.

    We understand we cannot do this alone, and that we need to
    work together in unprecedented and inclusive partnership with all
    stakeholders – political leaders, public and private sector partners,
    civil society, academia, and all other stakeholders across society
    – jointly leveraging our comparative strengths and respective
    voices to drive towards collective solutions, an accelerated path,
    and access for all. We are stronger, faster and more effective
    working together.

    Our Mission is not only accelerated development and availability
    of new COVID-19 tools – it is to accelerate equitable global access
    to safe, quality, effective, and affordable COVID-19 diagnostics,
    therapeutics and vaccines, and thus to ensure that in the fight
    against COVID-19, no one is left behind.

    Our Commitment

    1. We commit to the shared aim of equitable global
      access to innovative tools for COVID-19 for all.
    2. We commit to an unprecedented level of partnership
      – proactively engaging stakeholders, aligning and
      coordinating efforts, building on existing collaborations, collectively devising solutions, and grounding
      our partnership in transparency, and science.
    3. We commit to create a strong unified voice to
      maximize impact, recognizing this is not about
      singular decision-making authority, but rather
      collective problem-solving, interconnectedness and
      inclusivity, where all stakeholders can connect and
      benefit from the expertise, knowledge and activities
      of this shared action-oriented platform.
    4. We commit to build on past experiences towards
      achieving this objective, including ensuring that
      every activity we undertake is executed through the
      lens of equitable global access, and that the voices
      of the communities most affected are heard.
    5. We commit to be accountable to the world, to
      communities, and to one another. We are coming
      together in the spirit of solidarity, and in the service
      of humanity, to achieve our mission and vision.

    Our Call

    We ask the global community and political leaders to
    support this landmark collaboration, and for donors to
    provide the necessary resources to accelerate achievement
    of the objectives of this global collaboration, capitalizing
    on the opportunity provided by the rolling pledging
    campaign that will start on 4 May 2020.

    Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies
    Read More
    https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-action-global-collaboration-to-accelerate-new-covid-19-health-technologies

    Views: 0

  • Selling with Confidence: How to Keep Revenue and Prices Up

    Selling with confidence gives sales professionals the skills and support they need to resist growing pressure to discount prices. Such confidence is more critical than ever because the pressure to discount comes from two sources. First?no surprise?it comes from customers. In today?s world, when demand is slowing and globalization introduces low-cost competitors, existing and new customers are more insistent than ever that sales people discount and then discount some more. The battle to maintain profits by resisting discounting pressures from customers is tough enough without more pressure coming from yet a second source: the sales person?s sales managers and corporate executives.

    Read More
    http://www.associationofmarketing.org/whitepapers/view.php?whitepaper_id=71

    Views: 0